What’s Heron Therapeutics Inc (HRTX) Upside After Today’s Big Increase?

September 17, 2017 - By Nellie Frank

The stock of Heron Therapeutics Inc (NASDAQ:HRTX) is a huge mover today! The stock increased 5.12% or $0.75 on September 15, reaching $15.4. About 1.20M shares traded or 142.29% up from the average. Heron Therapeutics Inc (NASDAQ:HRTX) has declined 20.92% since September 17, 2016 and is downtrending. It has underperformed by 37.62% the S&P500.
The move comes after 7 months positive chart setup for the $833.74 million company. It was reported on Sep, 17 by Barchart.com. We have $16.02 PT which if reached, will make NASDAQ:HRTX worth $33.35 million more.

Investors wait Heron Therapeutics Inc (NASDAQ:HRTX) to report on November, 14. its quarterly earnings Wall Street analysts expect $-0.87 EPS, up $0.37 or 29.84 % from last year’s $-1.24 same quarter earnings. Heron Therapeutics Inc’s Wall Street analysts see 8.75 % negative EPS growth, taking into account the $-0.80 EPS reproted in the previous quarter,

Heron Therapeutics Inc (NASDAQ:HRTX) Ratings Coverage

Among 10 analysts covering Heron Therapeutics (NASDAQ:HRTX), 10 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Heron Therapeutics had 19 analyst reports since August 3, 2015 according to SRatingsIntel. On Wednesday, September 2 the stock rating was initiated by Bank of America with “Buy”. Cowen & Co maintained Heron Therapeutics Inc (NASDAQ:HRTX) rating on Friday, May 26. Cowen & Co has “Buy” rating and $4000 target. Cowen & Co maintained it with “Buy” rating and $4000 target in Thursday, August 3 report. The rating was maintained by Cantor Fitzgerald with “Buy” on Friday, August 18. Brean Capital maintained the stock with “Buy” rating in Monday, August 3 report. The firm earned “Buy” rating on Monday, August 10 by Brean Capital. Lake Street initiated it with “Buy” rating and $45 target in Thursday, December 10 report. The company was maintained on Tuesday, August 15 by Jefferies. The firm earned “Buy” rating on Wednesday, October 26 by Aegis Capital. The stock of Heron Therapeutics Inc (NASDAQ:HRTX) earned “Buy” rating by Jefferies on Wednesday, September 23.

More notable recent Heron Therapeutics Inc (NASDAQ:HRTX) news were published by: Reuters.com which released: “BRIEF-Heron Therapeutics appoints Robert Hoffman as CFO” on April 24, 2017, also Seekingalpha.com with their article: “Heron Therapeutics: Our Next Pick” published on August 14, 2017, Seekingalpha.com published: “Heron Therapeutics: CINV Franchise Provides Valuation Floor, Significant …” on February 04, 2017. More interesting news about Heron Therapeutics Inc (NASDAQ:HRTX) were released by: Seekingalpha.com and their article: “Heron Therapeutics: Giving A ‘Thumbs Up’ To This ~$14 Biopharma Stock” published on February 27, 2017 as well as Seekingalpha.com‘s news article titled: “Heron Therapeutics Shows Potential In The Chemotherapy-Induced-Nausea Market” with publication date: July 10, 2017.

Heron Therapeutics, Inc. is a biotechnology firm engaged in developing pharmaceutical products for patients suffering from cancer or pain. The company has market cap of $833.74 million. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. It currently has negative earnings. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: